

(Use as many sheets as necessary)

Sheet

1

2

4

Application Number	09/964,273
Filing Date	September 26, 2001
First Named Inventor	Sean Brynjelsen
Art Unit	1615
Examiner Name	P. A. Hawes
Attorney Docket Number	CPIFT-5776 (3360-0004)

[illegible]

**Examiner  
Signature**

Date  
Considered

11-21-2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2**

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet

b2

of

14

**Complete if Known**

Application Number	09/964,273
Filing Date	September 26, 2001
First Named Inventor	Sean Brynjelsen
Art Unit	1615
Examiner Name	P. A. Hawes
Attorney Docket Number	CPIFT-5776 (3360-0004)

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**


Date  
Considered

11-21-2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**American LegalNet, Inc.**  
**www.USCourtForms.com**



PTO/SB/08b (07-05)

Approved for use through 08/30/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of 4

**Complete If Known**

Application Number	09/964,273
Filing Date	September 26, 2001
First Named Inventor	Sean Brynjelsen
Art Unit	1615
Examiner Name	P. A. Hawes
Attorney Docket Number	CPIFT-5776 (3360-0004)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PAH	32	Kinman et al., "Lipid-Drug Association Enhanced HIV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2 <sub>87</sub> -Infected Macaques", Journal of Acquired Immune Deficiency Syndrome, 34(4), pp. 387-397	
	33	Limoges et al., poster presentation, 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004.	
	34	Moghim et al., "Long-Circulating and Target-Specific Nanoparticles: Theory to Practice", Pharmacological Reviews, 53, pp. 283-318, 2001.	
	35	Nesbit et al., "In Vitro and Animal Models of Human Immunodeficiency Virus Infection of the Central Nervous System", Clinical and Diagnostic Laboratory Immunology, 9(3), pp. 515- 524, May 2002.	
	36	Nottet et al., "HIV-1 Entry into Brain: Mechanisms for the Infiltration of HIV-1 infected Macrophages Across the Blood-Brain Barrier", The Neurology of AIDS, p. 55, 1998.	
	37	Perno et al., "Relative Potency of Protease Inhibitors in Monocytes/Macrophages Acutely and Chronically Infected with Human Immunodeficiency Virus", The Journal of Infectious Diseases, 178, pp. 413-422, 1998.	
	38	Sawchuk et al., "Investigation of distribution, transport and uptake of an anti-HIV drugs to the central nervous system", Advanced Drug Delivery Reviews, 39, pp. 5-31, 1999.	
	39	Solas et al., "Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients", Antimicrobiology Agents and Chemotherapy, 47 (1), pp. 238-243, January 2003.	
	40	Shrayer, et al., "Ceramide, a mediator of apoptosis, synergizes with paclitaxel to induce regression of the L 3.6 human pancreatic carcinoma implanted in SCD1 mice", Journal of Clinical Oncology, Vol. 22, No. 14S, Abstract, 2004:2135.	
	41	Schroeder et al., "Distribution of Radiolabeled Subvisible Microspheres after Intravenous Administration to Beagle Dogs", Journal of Pharmaceutical Sciences, Vol. 67, No. 4, pp. 504-507, April 1978.	

Examiner  
SignatureDate  
Considered


11-21-2005

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.  
www.USCourtForms.com



PTO/SB/08b (07-05)

Approved for use through 08/30/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/964,273
Filing Date	September 26, 2001
First Named Inventor	Sean Brynjelsen
Art Unit	1615
Examiner Name	P. A. Hawes
Attorney Docket Number	CPIFT-5776 (3360-0004)

Sheet 4

of 4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PLS	42	Allen et al., "Large unilamellar liposomes with low uptake into the reticuloendothelial system", FEB, Vol. 223, No. 1, pp. 42-46, 1987.	
	43	Allen et al., "Effects on the murine mononuclear phagocyte system of chronic administration of liposomes containing drug or lipid A compared with empty liposomes", Can. J. Physiol. Pharmacol., Vol. 65, pp. 185-190, 1987.	
	44	Graham, D.T., et al., "The Effects of Freezing on Commercial Insulin Suspensions", International Journal of Pharmaceutics, pp. 315-322, 1978.	
	45	Bender et al., "Efficiency of Nanoparticles as a Carrier for Antiviral Agents in Human Immunodeficiency Virus-Infected Human Monocytes/Macrophages In Vitro", Antimicrobial Agents and Chemotherapy, 40(6), pp. 1467-1471, June 1996.	
	46	H. von Briesen, "Controlled Release of Antiretroviral Drugs", AIDS Rev., 2, pp. 31-38, 2000.	
	47	Aquaro, et al., "Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir", Antiviral Research 55, pp. 209-225, 2002.	
	48	Crowe, et al., "The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection", Journal of Leukocyte Biology, Vol. 74, pp. 635-641, November 2003.	
	49	Fischer-Smith et al., "CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection", Journal of NeuroVirology, 7, pp. 528-541, 2001.	
PA	50	Igarashi et al., "Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans", PNAS, 98(2), pp. 658-663, January 16, 2001.	

Examiner  
SignatureDate  
Considered

11-21-2005

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.